CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 194 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.14 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $28,385 | +2645.2% | 1,903,701 | +1916.2% | 0.00% | – |
| Q2 2023 | $1,034 | +63.1% | 94,421 | +30.0% | 0.00% | – |
| Q1 2023 | $634 | -21.8% | 72,611 | -43.9% | 0.00% | – |
| Q4 2022 | $811 | -99.9% | 129,417 | -26.1% | 0.00% | – |
| Q3 2022 | $613,000 | +70.3% | 175,100 | +43.3% | 0.00% | – |
| Q2 2022 | $360,000 | +5.3% | 122,200 | +11.0% | 0.00% | – |
| Q1 2022 | $342,000 | +4.6% | 110,123 | +13.9% | 0.00% | – |
| Q4 2021 | $327,000 | -34.9% | 96,651 | -29.7% | 0.00% | – |
| Q3 2021 | $502,000 | -16.3% | 137,574 | 0.0% | 0.00% | – |
| Q2 2021 | $600,000 | +90.5% | 137,574 | +98.4% | 0.00% | – |
| Q1 2021 | $315,000 | +14.5% | 69,335 | +44.6% | 0.00% | – |
| Q4 2020 | $275,000 | +60.8% | 47,958 | +103.6% | 0.00% | – |
| Q3 2020 | $171,000 | -96.2% | 23,558 | -94.3% | 0.00% | -100.0% |
| Q3 2018 | $4,554,000 | -50.6% | 410,967 | -40.2% | 0.00% | 0.0% |
| Q2 2018 | $9,223,000 | +1.4% | 687,277 | -1.8% | 0.00% | 0.0% |
| Q1 2018 | $9,094,000 | – | 700,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 2,023,369 | $27,154,000 | 9.26% |
| Omega Fund Management, LLC | 551,477 | $7,401,000 | 5.46% |
| Foresite Capital Management III, LLC | 1,562,040 | $20,963,000 | 4.51% |
| Versant Venture Management, LLC | 1,048,601 | $14,072,225,000 | 4.39% |
| Boxer Capital, LLC | 2,094,000 | $28,101,000 | 3.18% |
| Opaleye Management Inc. | 697,500 | $9,360,000 | 2.42% |
| Abingworth LLP | 273,417 | $3,667,000 | 2.10% |
| DAFNA Capital Management LLC | 294,511 | $3,952,000 | 1.85% |
| NEXTHERA CAPITAL LP | 828,655 | $11,121,000 | 1.72% |
| Vivo Capital, LLC | 906,000 | $12,158,000 | 1.57% |